Skip to main content
Skip to section navigation
Skip to footer
Close
Our Technology
Our Technology
Nu.Q
®
Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
Our Tests
Our Nu.Q
®
tests provide a cost effective routine blood test for disease detection, treatment and monitoring.
Our Tests
Human Health
Nu.Q
®
NETs
Nu.Q
®
NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
Nu.Q
®
Discover
Buy our Nu.Q
®
Discover H3.1 Research Use Only Assay
Animal Health
Nu.Q
®
Vet Cancer Test
Nu.Q
®
Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Our Service
Use our assays to answer your clinical questions, such as measuring treatment efficacy, or on-target and off-target effects in drug development.
Our Service
Nu.Q
®
Discover
Nu.Q
®
Discover gives you access to a range of assays, built on our proprietary Nucleosomics™ platform, for rapid epigenetic profiling in disease model development, preclinical testing and clinical studies.
Our Pipeline Development
Our latest epigenetics developments.
Our Pipeline Development
Nu.Q
®
Cancer
We are developing a range of blood-based assays with potential applications beyond cancer detection.
Breakthrough Cancer Detection Method
We have developed a novel method for liquid biopsy enabling rapid, cost-effective cancer detection in a routine blood test.
Disease Areas
Human Health
Cancer
Sepsis
Products
Nu.Q® Products
Nu.Q
®
NETs
Nu.Q
®
NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
Nu.Q
®
Discover
Buy our Nu.Q
®
Discover H3.1 Research Use Only Assay
Nu.Q
®
Vet
Nu.Q
®
Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Resources
Resources
Press Releases
Latest news on Volition and our products.
Scientific
Resources for educational and research purposes.
Events & Webinars
Resources for educational and research purposes.
Media Toolkit & Downloads
Our library for images and educational downloads.
View all resources
Company
About
Our Company
Volition means to have determination and a purpose.
Our Team
Get to know our team of experts behind our research and products.
Careers
We’re always looking for talented individuals to join our mission.
Investors
Search for:
Join Mailing List
Investor Relations
All SEC Filings
.
Investors
Investors
Overview
News & Events
Overview
Press Releases
Video Gallery
IR Calendar
Presentations & Reports
Email Alerts
Shareholders Letters
Company Info
Company Profile
Executive Team
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Filing Type
View All
10-K
10-KT
10-KT/A
10-Q
10-Q/A
10KSB
10KSB/A
10QSB
10QSB/A
10SB12G
3
3/A
4
4/A
424B1
424B3
424B4
424B5
425
5
8-A12B
8-K
8-K/A
AW
CERTNYS
CORRESP
D
DEF 14A
DEFA14A
EFFECT
NT 10-K
NT 10-Q
POS AM
PRE 14A
RW
RW WD
S-1
S-1/A
S-3
S-3/A
S-8
SB-2
SB-2/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13G/A
UPLOAD
Year
View All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
SEC Filings
Date
Form
Description
XBRL
Pages
09/27/18
S-8
Form S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
8
09/26/18
CORRESP
Form CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
09/26/18
CORRESP
Form CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
2
09/26/18
S-3/A
Form S-3/A: Registration statement for specified transactions by certain issuers
57
09/18/18
UPLOAD
Form UPLOAD: SEC-generated letter
2
09/11/18
8-K
Form 8-K: Current report filing
21
09/10/18
S-3
Form S-3: Registration statement for specified transactions by certain issuers
92
09/07/18
SC 13G/A
Form SC 13G/A: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
7
08/27/18
D
Form D: Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.
7
08/20/18
4
Form 4: Statement of changes in beneficial ownership of securities
2
rss_feed
Filing RSS
Previous Page
arrow_back
Page
1
…
Page
63
Page
64
Page
65
Page
66
Page
67
Page
68
Page
69
Page
70
Page
71
Page
72
…
Page
106
Next Page
arrow_forward
Select a page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Page 30
Page 31
Page 32
Page 33
Page 34
Page 35
Page 36
Page 37
Page 38
Page 39
Page 40
Page 41
Page 42
Page 43
Page 44
Page 45
Page 46
Page 47
Page 48
Page 49
Page 50
Page 51
Page 52
Page 53
Page 54
Page 55
Page 56
Page 57
Page 58
Page 59
Page 60
Page 61
Page 62
Page 63
Page 64
Page 65
Page 66
Page 67
Page 68
Page 69
Page 70
Page 71
Page 72
Page 73
Page 74
Page 75
Page 76
Page 77
Page 78
Page 79
Page 80
Page 81
Page 82
Page 83
Page 84
Page 85
Page 86
Page 87
Page 88
Page 89
Page 90
Page 91
Page 92
Page 93
Page 94
Page 95
Page 96
Page 97
Page 98
Page 99
Page 100
Page 101
Page 102
Page 103
Page 104
Page 105
Page 106
email
Email Alerts
location_city
Company Profile
contact_page
Contacts
rss_feed
RSS News Feed
account_tree
Sitemap